tHEORetically Speaking
Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/
tHEORetically Speaking
Weekly News Roundup – Neuro Breakthroughs, Biosimilar Reform, and an Obesity Drug Showdown
•
HealthEconomics.com
•
Season 4
•
Episode 23
This week’s tHEORetically Speaking News Roundup covers Evotec and Bristol Myers Squibb’s progress in developing next-generation therapies for neurodegenerative diseases, the FDA’s game-changing move to streamline biosimilar approvals and lower drug costs, and Novo Nordisk’s bold $6.5B counteroffer to outbid Pfizer for Metsera in the obesity treatment race.
Tune in for this concise recap of the top stories shaping HEOR, RWE, and Market Access this week.